GlassScriptPhysician profile
John T Liu
NPI 1881734465
$2,452.66
in general payments reported to CMS, 2019-2025
25 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $140 · 2021: $584 · 2022: $531 · 2023: $232 · 2024: $285 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $945.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $448.87 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $272.97 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $250.67 | 2023-2025 | Evkeeza |
| Novartis Pharmaceuticals Corporation | $170.50 | 2019-2023 | |
| Cvrx, INC. | $169.05 | 2024 | Barostim Neo System |
| Medtronic, INC. | $157.44 | 2025 | Mazor X System |
| Alexion Pharmaceuticals, INC. | $146.54 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $124.97 | 2022 | |
| Jazz Pharmaceuticals INC. | $117.64 | 2025 | |
| Amgen INC. | $112.92 | 2020-2021 | |
| Pfizer INC. | $89.44 | 2024-2025 | |
| Allergan, INC. | $83.92 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $56.37 | 2020-2023 | |
| Otsuka America Pharmaceutical, INC. | $54.86 | 2023-2024 | Rexulti, Nuedexta |
| Novo Nordisk INC | $24.41 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $23.41 | 2021 | |
| Sunovion Pharmaceuticals INC. | $20.64 | 2019 | |
| Sun Pharmaceutical Industries INC. | $20.14 | 2021 | |
| Merck Sharp & Dohme LLC | $19.17 | 2019 | |
| Abbvie INC. | $18.06 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $17.08 | 2021 | |
| Astellas Pharma US INC | $15.07 | 2019 | |
| Abbott Laboratories | $15.04 | 2024 | Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.28 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.